Showing results (11-20 of 63) with videos related to
Sort By:
Pageof 7
Journal of Medicinal Chemistry|October 6, 2022
Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus InfectionsAlexander Birkmann, Susanne Bonsmann, Dirk Kropeit, et al.Antiviral Research|November 9, 2017
Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitisDebra C Quenelle, Alexander Birkmann, Thomas Goldner, et al.Antimicrobial Agents and Chemotherapy|April 23, 2014
Pharmacokinetics-pharmacodynamics of the helicase-primase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine herpes simplex virus 1 infection modelSubhajit Biswas, Soumi Sukla, Thomas Goldner, et al.Antiviral Research|March 28, 2025
Overview on the management of herpes simplex virus infections: Current therapies and future directionsAlexander Birkmann, Rob SaundersCurrent Opinion in Pharmacology|July 30, 2008
Antiviral strategies to combat cytomegalovirus infections in transplant recipientsPeter Lischka, Holger ZimmermannJAMA|December 21, 2016
Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical TrialAnna Wald, Burkhard Timmler, Amalia Magaret, et al.The Journal of Infectious Diseases|April 9, 2016
No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily TherapyPaul T Edlefsen, Alexander Birkmann, Meei-Li Huang, et al.Antiviral Research|February 1, 2015
Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovirThomas Goldner, Holger Zimmermann, Peter LischkaAntimicrobial Agents and Chemotherapy|March 18, 2015
In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replicationSteffen Wildum, Holger Zimmermann, Peter LischkaThe Journal of Infectious Diseases|June 27, 2015
Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)Peter Lischka, Detlef Michel, Holger ZimmermannPageof 7